Escarleth Fernandez

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).”.

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more